JP2008518598A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008518598A5 JP2008518598A5 JP2007539186A JP2007539186A JP2008518598A5 JP 2008518598 A5 JP2008518598 A5 JP 2008518598A5 JP 2007539186 A JP2007539186 A JP 2007539186A JP 2007539186 A JP2007539186 A JP 2007539186A JP 2008518598 A5 JP2008518598 A5 JP 2008518598A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- identified
- nucleotide sequence
- compounds
- classification
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 description 24
- 150000001875 compounds Chemical class 0.000 description 24
- 239000002773 nucleotide Substances 0.000 description 17
- 125000003729 nucleotide group Chemical group 0.000 description 17
- 238000000034 method Methods 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- 150000007523 nucleic acids Chemical class 0.000 description 12
- 108091033319 polynucleotide Proteins 0.000 description 12
- 102000040430 polynucleotide Human genes 0.000 description 12
- 239000002157 polynucleotide Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 11
- 102000039446 nucleic acids Human genes 0.000 description 10
- 108020004707 nucleic acids Proteins 0.000 description 10
- 108091026890 Coding region Proteins 0.000 description 9
- 230000001738 genotoxic effect Effects 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 230000000295 complement effect Effects 0.000 description 7
- 231100000024 genotoxic Toxicity 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 6
- 230000009274 differential gene expression Effects 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- BSJGASKRWFKGMV-UHFFFAOYSA-L ammonia dichloroplatinum(2+) Chemical compound N.N.Cl[Pt+2]Cl BSJGASKRWFKGMV-UHFFFAOYSA-L 0.000 description 4
- 229960004316 cisplatin Drugs 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 101150039504 6 gene Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000036978 cell physiology Effects 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 231100000025 genetic toxicology Toxicity 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 231100000804 nongenotoxic Toxicity 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 229960001756 oxaliplatin Drugs 0.000 description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000008649 adaptation response Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000003633 gene expression assay Methods 0.000 description 1
- 238000012203 high throughput assay Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62362804P | 2004-10-29 | 2004-10-29 | |
| PCT/US2005/039005 WO2006050124A2 (en) | 2004-10-29 | 2005-10-27 | Evaluation of the toxicity of pharmaceutical agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008518598A JP2008518598A (ja) | 2008-06-05 |
| JP2008518598A5 true JP2008518598A5 (enExample) | 2008-10-30 |
Family
ID=36319674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007539186A Pending JP2008518598A (ja) | 2004-10-29 | 2005-10-27 | 薬剤の毒性評価 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20080096770A1 (enExample) |
| EP (1) | EP1807539A2 (enExample) |
| JP (1) | JP2008518598A (enExample) |
| WO (1) | WO2006050124A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101903774A (zh) * | 2007-12-20 | 2010-12-01 | 弗·哈夫曼-拉罗切有限公司 | 预测基因毒性 |
| US20090181415A1 (en) * | 2007-12-20 | 2009-07-16 | Hans Marcus Ludwig Bitter | Prediction of genotoxicity |
| EP2281904A1 (en) * | 2009-07-28 | 2011-02-09 | Universiteit Maastricht | In vitro method for predicting whether a compound is genotoxic in vivo. |
| CA2777417A1 (en) * | 2009-10-21 | 2011-04-28 | Basf Plant Science Company Gmbh | Method for generating biomarker reference patterns |
| KR101134029B1 (ko) * | 2009-11-16 | 2012-04-13 | 한국과학기술연구원 | 인체 독성 유발 약물 탐색용 마커유전자 및 이를 이용한 탐색 방법 |
| GB0921712D0 (en) | 2009-12-11 | 2010-01-27 | Ge Healthcare Uk Ltd | Methods of detecting DNA damage |
| EP2639314A1 (en) * | 2012-03-14 | 2013-09-18 | Universiteit Maastricht | In vitro method for predicting whether a compound is genotoxic in vivo. |
| DK3149204T3 (en) | 2014-05-28 | 2021-10-25 | Predictomics Ab | In vitro toxicogenomics for toxicity prediction |
| EP3191591A1 (en) * | 2014-09-12 | 2017-07-19 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting complement component c5 and methods of use thereof |
| US20190325991A1 (en) * | 2016-12-28 | 2019-10-24 | National Institutes Of Biomedical Innovation, Health And Nutrition | Characteristic analysis method and classification of pharmaceutical components by using transcriptomes |
| JP2020025471A (ja) * | 2018-08-09 | 2020-02-20 | 国立研究開発法人産業技術総合研究所 | 毒性学習装置、毒性学習方法、学習済みモデル、毒性予測装置およびプログラム |
| JP6558786B1 (ja) * | 2018-09-28 | 2019-08-14 | 学校法人東北工業大学 | 標的の特性の予測を行うための方法、コンピュータシステム、プログラム |
| WO2021256837A1 (ko) * | 2020-06-15 | 2021-12-23 | 인제대학교 산학협력단 | 신장 질환 진단 또는 치료용 조성물 |
| CN111812167A (zh) * | 2020-07-15 | 2020-10-23 | 哈尔滨工业大学（深圳） | 一种化学品间接毒性检测平台及其应用 |
| WO2024202434A1 (ja) * | 2023-03-31 | 2024-10-03 | 富士フイルム株式会社 | 情報処理装置、情報処理方法、及びプログラム |
-
2005
- 2005-10-27 WO PCT/US2005/039005 patent/WO2006050124A2/en not_active Ceased
- 2005-10-27 EP EP05825039A patent/EP1807539A2/en not_active Withdrawn
- 2005-10-27 US US11/718,298 patent/US20080096770A1/en not_active Abandoned
- 2005-10-27 JP JP2007539186A patent/JP2008518598A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Newton et al. | The utility of DNA microarrays for characterizing genotoxicity. | |
| US20230039899A1 (en) | In situ rna analysis using probe pair ligation | |
| Ohnmacht et al. | Missing heritability in Parkinson’s disease: the emerging role of non-coding genetic variation | |
| DeSantis et al. | Rapid quantification and taxonomic classification of environmental DNA from both prokaryotic and eukaryotic origins using a microarray | |
| US10059989B2 (en) | Transposition of native chromatin for personal epigenomics | |
| Henihan et al. | Label-and amplification-free electrochemical detection of bacterial ribosomal RNA | |
| JP2008518598A5 (enExample) | ||
| Ruvindy et al. | Genomic copy number variability at the genus, species and population levels impacts in situ ecological analyses of dinoflagellates and harmful algal blooms | |
| ES2605228T3 (es) | Métodos para evaluar la capacidad de respuesta de un linfoma de células B al tratamiento con anticuerpos anti-CD40 | |
| KR20160080165A (ko) | 퇴행성 뇌질환 진단용 조성물 및 이를 이용한 퇴행성 뇌질환의 진단 방법 | |
| JPWO2018056432A1 (ja) | 血液検体の溶血を検出する方法及び溶血検出用チップ | |
| Aoki et al. | 384-Channel electrochemical sensor array chips based on hybridization-triggered switching for simultaneous oligonucleotide detection | |
| Sforza | Food authentication using bioorganic molecules | |
| KR101604178B1 (ko) | 약물에 의한 간 손상의 예측 및 진단을 위한 바이오마커 | |
| US20060223058A1 (en) | In vitro association studies | |
| US20100029492A1 (en) | Nucleic acid chip for obtaining binding profile of single strand nucleic acid and unknown biomolecule, manufacturing method thereof and analysis method of unknown biomolecule using nucleic acid chip | |
| CN101666805A (zh) | 特异性蛋白检测芯片的制备方法 | |
| KR20230028619A (ko) | 아토피성 피부염 진단용 바이오마커 및 이의 용도 | |
| EP3447154A1 (en) | Method for detection of mutations, polymorphisms and specific dna sequences on dna matrices with dna imaging techniques for the use in medical diagnostics and forensic genetics | |
| KR20180105597A (ko) | 샤르코-마리-투스 질환 진단용 키트 | |
| US20050003393A1 (en) | Psychoactive compound associated markers and method of use thereof | |
| Tu et al. | Rapid PCR-free meat species mitochondrial DNA identification using Electric Field Induced Release and Measurement (EFIRM®) | |
| CN117089636B (zh) | 分析山羊肉用性能的分子标记组合及应用 | |
| Beechem et al. | Evaluating the Technical Performance of Single-Cell Spatial Molecular Imaging Technologies | |
| KR20150081631A (ko) | 전사체학과 단백질체학을 이용한 약물에 의한 간 손상의 예측 및 진단을 위한 바이오마커 |